Sanofi to Present Dupixent CSU Phase 3 Data at ACAAI
Ticker: SNYNF · Form: 6-K · Filed: Oct 31, 2024 · CIK: 1121404
| Field | Detail |
|---|---|
| Company | Sanofi (SNYNF) |
| Form Type | 6-K |
| Filed Date | Oct 31, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trial-data, drug-development, press-release
Related Tickers: SNY
TL;DR
Sanofi presenting Dupixent Phase 3 CSU data at ACAAI next week - potential new indication.
AI Summary
On October 24, 2024, Sanofi announced that late-breaking Phase 3 data for Dupixent in chronic spontaneous urticaria (CSU) will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting. This presentation will include results from the LIBERTY-CSU-2 study, which evaluated Dupixent's efficacy and safety in adult patients with CSU.
Why It Matters
Positive Phase 3 data for Dupixent in chronic spontaneous urticaria could expand its therapeutic use and impact patient treatment options for this chronic condition.
Risk Assessment
Risk Level: low — This filing is an informational report of a press release and does not contain new financial or strategic information that would typically alter risk.
Key Players & Entities
- Sanofi (company) — Registrant
- Dupixent (company) — Drug name
- October 24, 2024 (date) — Press release date
- American College of Allergy, Asthma & Immunology (ACAAI) (company) — Conference name
- LIBERTY-CSU-2 (study) — Clinical trial name
FAQ
What is the significance of the data for Dupixent in chronic spontaneous urticaria?
The data relates to late-breaking Phase 3 results from the LIBERTY-CSU-2 study, which will be presented at the ACAAI Annual Scientific Meeting.
When was the press release regarding this data published?
The press release was dated October 24, 2024.
Which medical conference will feature the presentation of this data?
The data will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting.
What is the primary focus of the presented Dupixent data?
The data focuses on Dupixent's efficacy and safety in adult patients with chronic spontaneous urticaria (CSU).
What form type is this SEC filing?
This is a Form 6-K report.
Filing Stats: 185 words · 1 min read · ~1 pages · Grade level 12.6 · Accepted 2024-10-31 06:56:26
Filing Documents
- d901443d6k.htm (6-K) — 8KB
- d901443dex991.htm (EX-99.1) — 35KB
- g901443dsp001a.jpg (GRAPHIC) — 5KB
- g901443dsp001b.jpg (GRAPHIC) — 2KB
- 0001193125-24-248128.txt ( ) — 55KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: October 31, 2024 By SANOFI /s/ Alexandra Roger Name: Alexandra Roger Title: Head of Legal Corporate & Finance 3